Tumor specific vaccination therapy for advanced/recurrent ovarian cancer using HLA-A*2402 restricted Specific Epitope Peptides Cocktail derived from Tumor genome/Tumor related Angiogenetic factors genome

Cancer, ovarian
It is in a Phase I/II tumor specific vaccination therapy for advanced/recurrent ovarian cancer using HLA-A*2402 restricted specific epitope peptides cocktail derived from tumor genome/tumor related angiogenetic factors genome (Clinical trial, Trial ID:UMIN000003862, UMIN, JUL 2, 2010, View Source [SID1234520548]). Advanced/recurrent ovarian cancer with the conditions of unremoval by surgery, or refractory, chemo-resistant disease. Objective 1: To elcidate the feasibility and efficacy of HLA-A*2402 restricted Specific Epitope Peptides Cocktail of FOXM1,MELK,HJURP,VEGFR(vaacular endotherial growth factor receptor)-1 and VEGFR2. Objective 2: Safety,Efficacy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!